Mistras Group Announces Third Quarter Results
Nov 06, 2017 21:01 pm UTC| Business
Q3 Net Loss of ($7.0) million or ($0.25) per diluted share, including non-cash Intangible Asset Write-Off Pertaining to Products Subsidiary of ($9.8) million or ($0.33) net of tax;Excluding special items, the Company's net...
Manitex International, Inc. Provides Preliminary Summary Report on Third Quarter 2017 Operations
Nov 06, 2017 21:01 pm UTC| Business
BRIDGEVIEW, Ill., Nov. 06, 2017 -- Manitex International, Inc. (Nasdaq:MNTX) (the “Company"), a leading international provider of cranes and other specialized industrial equipment today announced that it has filed a...
Pernix Therapeutics Announces Sale of Non-Core Product
Nov 06, 2017 21:01 pm UTC| Business
MORRISTOWN, N.J., Nov. 06, 2017 -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) (“Pernix” or the “Company”), a specialty pharmaceutical company, today announced the sale of a non-core product, Cedax® (ceftibuten...
ECN Capital Schedules Q3-2017 Conference Call
Nov 06, 2017 21:01 pm UTC| Business
TORONTO, Nov. 06, 2017 -- ECN Capital Corp. (TSX:ECN) (“ECN Capital” or the “Company”), one of North America’s leading finance companies, today announced that it intends to file its financial statements and management...
Dermira and UCB Agree to End Collaboration Agreement for CIMZIA
Nov 06, 2017 21:01 pm UTC| Business
Dermira to transition development and commercialization responsibility for CIMZIA® (certolizumab pegol) in psoriasis back to UCBDecision reflects both companies’ strategic prioritiesUCB remains committed to bringing CIMZIA...
Nuvectra to Present at the Stifel 2017 Healthcare Conference
Nov 06, 2017 21:01 pm UTC| Business
PLANO, Texas, Nov. 06, 2017 -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that Scott Drees, Chief Executive Officer, and Walter Berger, Chief Operating Officer Chief...
Endocyte Reports Third Quarter Financial Results
Nov 06, 2017 21:01 pm UTC| Business
– Plans to Initiate Phase 3 Registration for 177Lu-PSMA-617 Accelerated by Radiomedix Agreement to Transfer Active U.S. Investigational New Drug Application (IND) to Endocyte – – The University of Sydney...